Tubulointerstitial Nephritis Pathology

Cellular and Molecular Mechanisms

• Drug-induced hypersensitivity reaction: NSAIDs, antibiotics (particularly β-lactams and fluoroquinolones), and proton pump inhibitors trigger Type IV hypersensitivity reactions through hapten-mediated T cell activation. The offending drug acts as a hapten, binding to tubular basement membrane or interstitial proteins, presenting novel antigens to CD8+ cytotoxic T lymphocytes and CD4+ helper T cells. This explains the delayed onset (typically 3-10 days after drug exposure) and eosinophilia characteristic of drug-induced TIN.

• Tubular epithelial injury and loss of barrier function: Direct toxic effects on proximal tubular epithelial cells lead to mitochondrial dysfunction, oxidative stress generation via reactive oxygen species (ROS), and activation of apoptotic pathways. Loss of tight junction proteins (claudins, occludin, ZO-1) disrupts the epithelial barrier, allowing luminal contents to leak into the interstitium and perpetuating inflammatory responses through danger-associated molecular patterns (DAMPs).

• Interstitial inflammation and fibrosis: Infiltrating lymphocytes (predominantly CD8+ T cells, with lesser CD4+ and CD20+ B cells) and macrophages/dendritic cells secrete pro-inflammatory cytokines (TNF-α, IL-2, IFN-γ) and chemokines (CCL2/MCP-1, CXCL10). Persistent inflammation drives myofibroblast activation, excessive extracellular matrix deposition (collagen I and III), and progression to interstitial fibrosis and tubular atrophy (IF/TA), the pathological hallmark of chronic kidney disease.

• Complement activation: Both classical and alternative pathways may be activated depending on etiology. In immune-complex mediated TIN, C1q and C3 deposition occurs along the tubular basement membrane (TBM), amplifying the inflammatory cascade. Complement-derived fragments (C3a, C5a) recruit and activate neutrophils and macrophages.

• Renin-angiotensin-aldosterone system (RAAS) activation: Tubular injury and reduced glomerular filtration rate trigger secondary RAAS activation, promoting efferent arteriolar vasoconstriction, worsening renal perfusion and perpetuating ischemic injury to surviving tubular segments.

Drug-Induced TIN (Most Common Cause ~70% of Cases)

• NSAIDs: Most frequent cause; mechanism involves both hypersensitivity (acute TIN with eosinophilic infiltration) and acute tubular necrosis from hemodynamic effects (inhibition of protective renal prostaglandins). Risk increased with volume depletion, advanced age, and underlying chronic kidney disease.

• Antibiotics: β-lactams (penicillins and cephalosporins) are classic triggers via hapten mechanism; aminoglycosides cause dose-dependent acute tubular necrosis; fluoroquinolones, trimethoprim-sulfamethoxazole, vancomycin, and rifampin also implicated.

• Proton pump inhibitors: Emerging cause; omeprazole most common, presenting with delayed-onset TIN weeks to months after initiation; mechanism incompletely understood but involves immune-mediated injury.

• Other medications: Diuretics, ACE inhibitors/angiotensin receptor blockers (paradoxically, especially in specific patient populations), NSAIDs, allopurinol, azathioprine, NSAIDs, chemotherapy agents (immune checkpoint inhibitors increasingly recognized).

Infection-Related TIN

• Bacterial pyelonephritis: Direct bacterial invasion of tubules and interstitium with abscess formation; acute suppurative TIN with neutrophilic microabscesses characteristic of acute pyelonephritis.

• Viral infections: EBV, CMV, HIV, and SARS-CoV-2 directly infect tubular epithelial cells; hantavirus causes hemorrhagic fever with renal syndrome featuring severe TIN.

• Mycobacterial infection: Tuberculosis causes granulomatous TIN with caseating granulomas in the interstitium; can progress to obstructive uropathy from strictures.

Autoimmune/Systemic Diseases

• Anti-tubular basement membrane disease: Rare condition with linear IgG deposition along the TBM on immunofluorescence; may occur alone or with anti-GBM disease.

• IgG4-related disease: IgG4+ plasma cell infiltration of the interstitium with storiform fibrosis and obliterative phlebitis; part of systemic disorder affecting multiple organs.

• Systemic lupus erythematosus (SLE): TIN can occur independently of lupus nephritis; characterized by lymphoplasmacytic infiltration with immune complex deposition.

• Sjögren syndrome: TIN with lymphoid infiltrates (primarily CD8+ T cells) causing tubulointerstitial inflammation; may present as renal tubular acidosis due to proximal tubular dysfunction.

Metabolic and Obstructive Causes

• Urate nephropathy: Monosodium urate crystal deposition in tubular lumens and interstitium causing acute or chronic TIN; occurs with high uric acid states (tumor lysis syndrome, gout, high purine diets).

• Light chain disease: Monoclonal immunoglobulin light chains (kappa or lambda) accumulate in tubular epithelial cells and interstitium, causing cast nephropathy (myeloma kidney) and secondary TIN.

• Contrast-induced nephropathy: Hyperosmolar radiocontrast agents cause osmotic injury to proximal tubular epithelium and medullary ischemia; associated TIN contributes to acute kidney injury in susceptible patients.

• Nephrolithiasis: Obstruction-induced ischemic injury and downstream TIN; chronic obstruction leads to permanent tubular atrophy and interstitial scarring.

Environmental/Occupational Exposures

• Heavy metals: Lead, mercury, and cadmium cause chronic TIN with progressive renal insufficiency; lead exposure associated with gout and secondary uric acid nephropathy.

• Herbal remedies: Aristolochic acid (present in some traditional medicines) causes aristolochic acid nephropathy (AAN), a rapidly progressive TIN with high malignancy risk (urothelial carcinoma).

Acute Tubulointerstitial Nephritis

• Cardinal symptoms: Nonspecific constitutional symptoms including fever (present in ~50% of cases), rash (maculopapular or urticarial in hypersensitivity reactions), and arthralgia/arthritis (classic triad in drug-induced TIN). Flank pain may occur with infection-related TIN or obstructive causes.

• Renal manifestations: Rapid rise in serum creatinine over days to weeks; oliguria possible in severe cases; non-nephrotic proteinuria (<3.5 g/24 hours); microscopic hematuria common.

• Urinalysis findings: Pyuria (white blood cell casts, white blood cells) and hematuria without red blood cell casts distinguish TIN from post-infectious glomerulonephritis; sterile pyuria (absence of bacteria despite urinary WBCs) is characteristic of drug-induced TIN.

• Eosinophiluria: Hansel stain or Wright-Giemsa staining reveals eosinophils in urine, highly suggestive of hypersensitivity-mediated TIN (drug-induced or other allergic etiologies); sensitivity ~40-50%, specificity ~90%.

• Physical examination findings: Fever and rash typical in hypersensitivity TIN; costovertebral angle tenderness in infectious pyelonephritis; edema less common than in nephrotic syndromes; hypertension variable depending on fluid status and degree of renal dysfunction.

Chronic Tubulointerstitial Nephritis

• Progressive renal insufficiency: Insidious rise in creatinine and decreased GFR without acute symptoms; patients often discovered to have kidney disease incidentally during routine labs.

• Metabolic complications: Hyperkalemia, hyperphosphatemia, hypocalcemia with secondary hyperparathyroidism, and metabolic acidosis (due to loss of ammonia excretion capacity).

• Polyuric renal failure: Unique to some forms of chronic TIN (lead nephropathy, aristolochic acid nephropathy); polyuria and nocturia reflecting tubular dysfunction and loss of concentrating ability, paradoxically worsening renal function.

• Hypertension: Develops in majority of chronic TIN patients from sodium retention, RAAS activation, and sympathetic nervous system activation; contributes to progressive decline in renal function and cardiovascular morbidity.

Infection-Related TIN (Pyelonephritis)

• Acute pyelonephritis: High fever (often >39°C), costovertebral angle tenderness, dysuria, and urinary frequency; positive urine and blood cultures; may progress to sepsis if untreated.

• Chronic pyelonephritis: May be asymptomatic; discovered on imaging showing renal scarring; associated with vesicoureteral reflux in children and obstructive uropathy in adults.

Laboratory Correlates

• Serum creatinine elevation: Usually disproportionate to degree of proteinuria; may reach 4-6 mg/dL in severe acute TIN before improvement with offending agent removal.

• Blood urea nitrogen (BUN): Typically elevated; BUN/Cr ratio variable depending on hydration status and timeline of kidney injury.

• Urinary biomarkers: Fractional excretion of sodium (FENa) typically >2% (indicates intrinsic renal disease rather than prerenal azotemia); N-acetyl-β-D-glucosaminidase (NAG) and kidney injury molecule-1 (KIM-1) elevated reflecting tubular injury.

Histopathological Findings (Gold Standard)

• Interstitial edema and inflammation: Acute TIN characterized by edematous expansion of the interstitium with mononuclear cell infiltration dominated by T lymphocytes (CD8+ > CD4+) and macrophages; typically preserved interstitial volume and architecture at this stage. Chronic TIN shows dense lymphoplasmacytic infiltration, interstitial fibrosis (collagen deposition), and tubular atrophy.

• Tubular involvement: Epithelial flattening and degeneration of tubular epithelial cells; loss of brush border in proximal tubules; tubular basement membrane disruption in severe cases. Tubular basement membrane may appear thickened, split, or frayed depending on etiology. Casts composed of light chains, uric acid crystals, or other substances visible in tubular lumens.

• Eosinophilic infiltration: Peripheral eosinophils and tissue eosinophils characterize drug hypersensitivity reactions; eosinophil-predominant interstitial inflammation highly specific for hypersensitivity TIN (NSAIDs, antibiotics, proton pump inhibitors).

• Granulomas: Noncaseating granulomas suggest sarcoidosis or drug reaction (allopurinol); caseating granulomas characteristic of tuberculosis. Granulomas typically located in the interstitium around blood vessels or tubules.

• Infection-specific findings: Neutrophilic microabscesses with bacterial organisms (identifiable by Gram stain or cultures) pathognomonic for acute suppurative pyelonephritis; areas of necrosis and hemorrhage may accompany severe infection.

• Glomerular preservation: Glomeruli typically normal or minimally involved in primary TIN; glomerular involvement suggests overlap with glomerulonephritis or systemic disease (SLE, vasculitis).

• Vascular involvement: Arteriolar hyalinosis may be present, reflecting chronic hypertension as a consequence of TIN; necrotizing vasculitis suggests ANCA-associated disease or other systemic vasculitis.

Immunofluorescence Microscopy

• Drug-induced TIN: Usually negative immunofluorescence (no immune complex deposition); absence of immunoglobulin and complement deposition helps exclude primary glomerulonephritis.

• Anti-TBM disease: Linear IgG deposition along tubular basement membrane, similar to anti-GBM disease but restricted to the TBM; may have concurrent linear GBM deposition.

• IgG4-related disease: Strong IgG and IgG4 staining in plasma cell infiltrates; may show IgG4/IgG ratio >40%.

• SLE-related TIN: Granular deposits of IgG, IgA, IgM, and complement in the interstitium; concurrent glomerular deposits suggest full lupus nephritis overlap.

Electron Microscopy

• Ultrastructure of tubular epithelium: Reveals mitochondrial swelling, cristae disruption, and cytoplasmic vacuolization in drug-induced or toxic TIN.

• Tubular basement membrane abnormalities: Splitting and lamination of TBM creates basket-weave appearance characteristic of anti-TBM disease; contrast with thin basement membrane disease (benign) or thickening from chronic disease.

• Electron-dense deposits: May be present in immune complex-mediated TIN; helpful in characterizing specific etiology.

Imaging Findings

• Ultrasound: Echogenicity increased in chronic TIN reflecting interstitial fibrosis; kidney size normal or small in chronic disease; preserved corticomedullary differentiation initially but may be lost with progressive scarring. Hydronephrosis suggests obstructive etiology.

• CT imaging: Delayed or heterogeneous enhancement of renal parenchyma reflecting reduced perfusion and interstitial edema; useful for identifying obstructing stones, renal masses, or renal vein thrombosis as alternative diagnoses.

• MRI: Not routinely indicated but useful in contrast-allergic patients; can assess renal perfusion and degree of fibrosis in research settings.

Laboratory Studies

• Complete metabolic panel: Elevated creatinine and BUN; hyperkalemia (from reduced tubular potassium secretion); hyperphosphatemia (from reduced GFR and altered phosphate handling); metabolic acidosis (from reduced ammonia excretion).

• Urinalysis: Pyuria without bacteriuria (sterile pyuria) classic for drug-induced TIN; microscopic or gross hematuria; non-nephrotic proteinuria typically <3 g/24 hours; white blood cell casts may be present.

• Urine eosinophils: Hansel stain for increased eosinophils; >1% eosinophils or >5 eosinophils/hpf highly suggestive of hypersensitivity TIN.

• Serological studies: ANA, anti-dsDNA, anti-Smith for SLE evaluation; ANCA panel (MPO-ANCA, PR3-ANCA) for vasculitis; Anti-GBM antibodies if anti-T

Immediate stabilisation

• Assess for emergent dialysis indications first: refractory hyperkalemia, severe metabolic acidosis, diuretic-resistant volume overload/pulmonary edema, and uremic complications (pericarditis, encephalopathy) are the KDIGO Acute Kidney Injury guideline's triggers for starting renal replacement therapy; no absolute BUN or creatinine number mandates dialysis.
• Optimise perfusion and stop nephrotoxins: KDIGO recommends isotonic crystalloid for volume depletion, avoidance of NSAIDs, aminoglycosides, and iodinated contrast, and renal dose-adjustment of all remaining drugs. If vancomycin is still required, dose to a 24-hour AUC/MIC of 400–600 per the IDSA/ASHP consensus rather than to a trough.

First-line therapy

• Withdrawal of the offending agent is the definitive treatment of drug-induced TIN and is the single best next step in almost every vignette. Because injury is a delayed type IV hypersensitivity response, creatinine often continues to rise for several days after the drug is stopped before recovering.
• Etiology-directed therapy: antimicrobials for pyelonephritis following the IDSA urinary tract infection guidance (ceftriaxone or a fluoroquinolone, narrowed by culture); RIPE therapy for renal tuberculosis per CDC/IDSA/ATS; urate-lowering therapy for urate nephropathy — rasburicase (screen for G6PD deficiency first; it is contraindicated because of hemolysis and methemoglobinemia) for tumor lysis–associated hyperuricemia, with the xanthine oxidase inhibitor allopurinol used chiefly for prevention rather than treatment of established urate load; relief of obstruction when hydronephrosis is present.

Escalation

• Corticosteroids: prednisone roughly 1 mg/kg/day (or pulse methylprednisolone in severe disease) with taper over weeks, generally reserved for biopsy-proven disease that fails to improve within about a week of drug withdrawal. Evidence is observational; benefit is greatest before interstitial fibrosis and tubular atrophy are established.
• Steroid-sparing agents: mycophenolate mofetil in steroid-dependent or refractory disease; rituximab for IgG4-related tubulointerstitial disease. Checkpoint-inhibitor nephritis is managed by holding the drug plus corticosteroids per the ASCO immune-related adverse event guideline.

Contraindicated

• Rechallenge with the culprit drug — may provoke fulminant recurrence.
• Empiric steroids in infection-related or granulomatous infectious TIN before the organism is treated.
• NSAIDs and continued ACEI/ARB during hyperkalemic AKI; RAAS blockade is typically held and later resumed.

Emergencies

• Hyperkalemia: impaired distal tubular potassium secretion (a hyperkalemic distal/type 4 pattern) plus falling GFR; signalled by peaked T waves, PR prolongation, and QRS widening. Management follows stabilize → shift → remove: membrane stabilization with IV calcium gluconate; intracellular shift with insulin plus dextrose, high-dose nebulized beta-2 agonist (albuterol), and sodium bicarbonate if the patient is acidemic; then potassium removal with a loop diuretic if urine output is preserved, a GI potassium binder, or dialysis if refractory or oligoanuric (KDIGO AKI).
• Diuretic-resistant volume overload with pulmonary edema: sodium retention from tubular injury; hypoxemia and diffuse crackles signal it.
• Uremic pericarditis or encephalopathy: retained uremic toxins; a friction rub or asterixis is an absolute indication for urgent dialysis.
• Urosepsis / emphysematous pyelonephritis: bacterial invasion of the interstitium; gas on CT with hemodynamic instability mandates source control and IDSA-directed antimicrobials.

Renal complications

• Progression to CKD and ESRD: unresolved interstitial inflammation drives myofibroblast activation and interstitial fibrosis with tubular atrophy; signalled by a creatinine that plateaus above baseline and persistent proteinuria after drug withdrawal (KDIGO 2024 CKD guideline staging by eGFR and albuminuria).
• Distal (type 1) RTA: lymphocytic destruction of collecting duct intercalated cells with loss of the apical H+-ATPase; non-anion-gap metabolic acidosis with hypokalemia, urine pH that cannot fall below ~5.5, and nephrocalcinosis/nephrolithiasis — classic in Sjögren syndrome and with amphotericin B.
• Proximal (type 2) RTA / Fanconi syndrome: proximal tubular injury causes bicarbonaturia, glycosuria with normal serum glucose, phosphaturia, and aminoaciduria — seen with aristolochic acid nephropathy, light chain proximal tubulopathy, tenofovir, ifosfamide, and lead.
• Nephrogenic diabetes insipidus / polyuric renal failure: medullary interstitial scarring destroys the concentrating gradient; nocturia with dilute urine despite rising creatinine.
• Papillary necrosis: analgesic (NSAID/phenacetin) nephropathy with medullary ischemia; gross hematuria, colicky flank pain, and sloughed papillae on CT urography.
• Urothelial carcinoma: aristolochic acid is directly mutagenic; painless hematuria years later.

Treatment-related

• Corticosteroid toxicity: hyperglycemia, infection (including reactivation of latent TB), psychiatric symptoms, adrenal suppression on abrupt withdrawal, osteoporosis, and avascular necrosis.
• Mycophenolate: cytopenias, diarrhea, and teratogenicity — pregnancy must be excluded.
• Dialysis access complications: catheter-related bloodstream infection and intradialytic hypotension prolonging tubular ischemia.

• The single best next step is stopping the culprit drug, not starting steroids and not dialysis. Expect creatinine to keep climbing for several days first — that lag is the type IV hypersensitivity mechanism, not treatment failure.
• Urine sediment decides the compartment: WBC casts with sterile pyuria = tubulointerstitial; RBC casts with dysmorphic RBCs = glomerulonephritis; muddy brown granular casts = acute tubular necrosis. This triad of casts is the most heavily tested discriminator on Step 1 and Step 2 CK.
• The classic triad of fever, rash, and eosinophilia occurs in only a minority of drug-induced cases, and its absence never excludes the diagnosis — a favourite distractor.
• Eosinophiluria is a trap: modest sensitivity and imperfect specificity mean a negative Hansel stain does not rule out TIN, and a positive one does not rule it in. Kidney biopsy remains the gold standard when the diagnosis changes management.
• Timing fingerprints the drug: β-lactams cause TIN within days to about two weeks; proton pump inhibitors and NSAIDs are notoriously delayed by weeks to months, so the offending agent may not be the newest one on the list.
• NSAID-induced TIN is the exception that breaks the rules: it often lacks fever, rash, and eosinophilia and can present with nephrotic-range proteinuria from concurrent minimal change disease — the association examiners love.
• Noncaseating granulomas in the interstitium plus hypercalcemia point to sarcoidosis (macrophage 1α-hydroxylase converting 25-OH vitamin D); caseating granulomas point to tuberculosis, and allopurinol is the classic drug cause of granulomatous TIN.
• Corticosteroids are second-line and time-sensitive, considered when biopsy-proven disease fails to improve after drug withdrawal and before fibrosis sets in; they are not used empirically in infection-driven TIN.